SG11201906931QA - Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation - Google Patents
Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillationInfo
- Publication number
- SG11201906931QA SG11201906931QA SG11201906931QA SG11201906931QA SG11201906931QA SG 11201906931Q A SG11201906931Q A SG 11201906931QA SG 11201906931Q A SG11201906931Q A SG 11201906931QA SG 11201906931Q A SG11201906931Q A SG 11201906931QA SG 11201906931Q A SG11201906931Q A SG 11201906931QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- atrial fibrillation
- louisiana
- nitrite
- pct
- Prior art date
Links
- 206010003658 Atrial Fibrillation Diseases 0.000 title abstract 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 title abstract 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 title abstract 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229910052945 inorganic sulfide Inorganic materials 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B21/00—Nitrogen; Compounds thereof
- C01B21/20—Nitrogen oxides; Oxyacids of nitrogen; Salts thereof
- C01B21/50—Nitrous acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B17/00—Sulfur; Compounds thereof
- C01B17/16—Hydrogen sulfides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
International Publication Date (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2018/152509 Al onion °nolo HE ioo Homo iflo oimIE (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) 23 August 2018 (23.08.2018) WIP0 I PCT (51) International Patent Classification: 3810 W. Lakeshore Drive, Baton Rouge, Louisiana 70808 A61K 33/02 (2006.01) C01B 17/16 (2006.01) (US). A61K 33/04 (2006.01) C01B 17/22 (2006.01) A61K 36/31 (2006.01) C01B 21/20 (2006.01) (74) Agent: HOLOUBEK, Charles G. et al.; 112 Pleasant A61K 45/06 (2006.01) C01B 21/24 (2006.01) Street, Concord, New Hampshire 03301 (US). (21) International Application Number: PCT/US2018/018750 (22) International Filing Date: 20 February 2018 (20.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/461,028 20 February 2017 (20.02.2017) US (71) Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICUL- TURAL AND MECHANICAL COLLEGE [US/US]; 3810 W. Lakeshore Drive, Baton Rouge, Louisiana 70808 (US). (72) Inventors: KEVIL, Christopher G.; 2815 Falmoth Dri- ve, Shreveport, Louisiana 71106 (US). DOMINIC, Paari; (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, O 00 O C (54) Title: HYDROGEN SULFIDE AND/OR NITRITE IN THE TREATMENT AND PREVENTION OF ATRIAL FIBRILLATION FIG. 1 (57) : A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, com- prising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both or- ganic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof. [Continued on next page] WO 2018/152509 Al MIDEDIMOMMIONE10130M1100110HOMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461028P | 2017-02-20 | 2017-02-20 | |
| PCT/US2018/018750 WO2018152509A1 (en) | 2017-02-20 | 2018-02-20 | Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906931QA true SG11201906931QA (en) | 2019-09-27 |
Family
ID=63169976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906931QA SG11201906931QA (en) | 2017-02-20 | 2018-02-20 | Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11116731B2 (en) |
| EP (1) | EP3582791A4 (en) |
| JP (1) | JP2020508308A (en) |
| AU (1) | AU2018220635A1 (en) |
| CA (1) | CA3052206A1 (en) |
| IL (1) | IL268804B2 (en) |
| SG (1) | SG11201906931QA (en) |
| WO (1) | WO2018152509A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220273702A1 (en) * | 2021-02-25 | 2022-09-01 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hydrogen sulfide and nitric oxide therapy for covid-19 infection |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (en) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
| AUPQ672800A0 (en) * | 2000-04-06 | 2000-05-04 | Natraherbal Pty Ltd | Garlic supplement for deodoriser |
| US20040110691A1 (en) | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
| AU2004257693B8 (en) | 2003-07-09 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
| FR2902659A1 (en) * | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | DHA ESTER AND ITS USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES |
| US10463689B2 (en) * | 2009-10-14 | 2019-11-05 | Board Of Supervisors Of Louisiana State University | Pharmaceutical formulations of nitrite and uses thereof |
| WO2012142413A2 (en) * | 2011-04-14 | 2012-10-18 | Theravasc Inc. | Nitrite compositions and uses thereof |
| WO2013025790A2 (en) | 2011-08-15 | 2013-02-21 | Research Foundation Of The City University Of New York | No- and h2s- releasing compounds |
| WO2014066285A1 (en) * | 2012-10-24 | 2014-05-01 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Plasma h2s levels as biomarkers for vascular disease |
| EP2994165A4 (en) * | 2013-05-10 | 2017-01-04 | Nitromega Corp. | Nutritional or dietary supplements containing fatty acids and nitrite |
| WO2015002612A1 (en) | 2013-07-01 | 2015-01-08 | Singapore Health Services Pte Ltd | Methods of screening using interstitial cells and methods of suppressing proliferation and/or transformation of interstitial cells |
-
2018
- 2018-02-20 US US16/486,596 patent/US11116731B2/en active Active
- 2018-02-20 SG SG11201906931QA patent/SG11201906931QA/en unknown
- 2018-02-20 AU AU2018220635A patent/AU2018220635A1/en not_active Abandoned
- 2018-02-20 CA CA3052206A patent/CA3052206A1/en active Pending
- 2018-02-20 EP EP18754890.4A patent/EP3582791A4/en not_active Withdrawn
- 2018-02-20 JP JP2019544834A patent/JP2020508308A/en active Pending
- 2018-02-20 WO PCT/US2018/018750 patent/WO2018152509A1/en not_active Ceased
- 2018-02-20 IL IL268804A patent/IL268804B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190365669A1 (en) | 2019-12-05 |
| IL268804B (en) | 2022-12-01 |
| US11116731B2 (en) | 2021-09-14 |
| EP3582791A1 (en) | 2019-12-25 |
| AU2018220635A1 (en) | 2019-08-15 |
| IL268804B2 (en) | 2023-04-01 |
| WO2018152509A1 (en) | 2018-08-23 |
| IL268804A (en) | 2019-10-31 |
| CA3052206A1 (en) | 2018-08-23 |
| EP3582791A4 (en) | 2021-03-31 |
| JP2020508308A (en) | 2020-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201804281RA (en) | Suture deployment of prosthetic heart valve | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201903582UA (en) | Settlement method, entrance control method, and apparatus | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201811180PA (en) | Communication methods, computer-readable media, communication devices, and servers | |
| SG11201902974PA (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds | |
| SG11201900471VA (en) | Combination therapy for copd | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |